165 related articles for article (PubMed ID: 31222826)
1. Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia.
Tervonen HE; Chen TYT; Lin E; Boyle FM; Moylan EJ; Della-Fiorentina SA; Beith J; Johnston A; Currow DC
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13125. PubMed ID: 31222826
[TBL] [Abstract][Full Text] [Related]
2. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
[TBL] [Abstract][Full Text] [Related]
3. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
Reeder-Hayes KE; Meyer AM; Hinton SP; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2017 Oct; 35(29):3298-3305. PubMed ID: 28727517
[TBL] [Abstract][Full Text] [Related]
4. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
5. Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients.
Lotan E; Leader A; Lishner M; Gottfried M; Pereg D
Anticancer Drugs; 2012 Oct; 23(9):991-5. PubMed ID: 22728764
[TBL] [Abstract][Full Text] [Related]
6. Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
Li W; Kwok CC; Chan DC; Wang F; Tse LA
Breast Cancer Res Treat; 2018 Apr; 168(2):483-493. PubMed ID: 29230661
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
8. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Nitz U; Gluz O; Clemens M; Malter W; Reimer T; Nuding B; Aktas B; Stefek A; Pollmanns A; Lorenz-Salehi F; Uleer C; Krabisch P; Kuemmel S; Liedtke C; Shak S; Wuerstlein R; Christgen M; Kates RE; Kreipe HH; Harbeck N;
J Clin Oncol; 2019 Apr; 37(10):799-808. PubMed ID: 30785826
[TBL] [Abstract][Full Text] [Related]
9. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
10. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
JAMA Oncol; 2018 Sep; 4(9):1199-1206. PubMed ID: 29852043
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.
Bayo J; Aviñó V; Toscano F; Jiménez F
Breast J; 2018 Jul; 24(4):462-467. PubMed ID: 29205665
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP; Ahn JH; Kim SB; Jung KH; Yoon DH; Lee JS; Ahn SH
Cancer Chemother Pharmacol; 2012 May; 69(5):1221-7. PubMed ID: 22271208
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea.
Kim HS; Lee SY; Kim JW; Choi YJ; Park IH; Lee KS; Seo JH; Shin SW; Kim YH; Kim JS; Park KH
Oncology; 2016; 91(5):274-282. PubMed ID: 27623006
[TBL] [Abstract][Full Text] [Related]
16. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
17. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Ip EJ; Lee-Ma A; Troxell LS; Chan J
Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
Abdel-Rahman O
Clin Transl Oncol; 2019 Feb; 21(2):239-245. PubMed ID: 29956074
[TBL] [Abstract][Full Text] [Related]
19. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
20. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
